AUSTIN, Texas, Aug. 30, 2021 (GLOBE NEWSWIRE) – XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the arrival of Mark Ziats, MD Ph.D., as Chief Medical Officer. Dr. Ziats will participate in the development and management of a diverse clinical portfolio for the Company’s drug candidates. The company is developing new drugs, including those for the treatment of cardiovascular disease, cancer, arthritis and infectious diseases. Dr Ziats will work with a multidisciplinary team, comprising key opinion leaders in the respective medical fields, to facilitate the clinical development of the Company’s drug candidates in all fields.
Dr Ziats received his medical training in Texas, from the Baylor College of Medicine in Houston; he obtained his doctorate in genetics from the University of Cambridge, England, under the NIH-Cambridge Biomedical Scholars Program; and he completed his residency in internal medicine at the University of Michigan. Mark Ziats is board certified by the American Board of Internal Medicine, has practiced general hospital medicine and post-acute health care, and has served as an assistant clinical professor of teaching at the University’s Greenville School of Medicine. from South Carolina. Dr. Ziats has authored publications on his research in the areas of neurodevelopment, clinical genetics and immune signaling pathways.
John Simard, CEO of XBiotech, said: “I am pleased to welcome Dr Ziats to XBiotech. His intelligence and energy will strengthen XBiotech and our clinical program. The pursuit of the company’s extraordinary mission of using the human body’s natural antibodies to treat disease is undoubtedly worthy of his talents. “
Mark Ziats commented: “I am very happy to join the XBiotech team as it has already demonstrated the impact that True Human antibody treatments can have. I believe this important and new technology can be further developed to improve the lives of many patients with a wide range of conditions. “
About True Human ™ Therapeutic Antibodies
XBiotech’s True Human ™ antibodies are derived, without modification, from individuals who possess natural immunity to certain diseases. Through clinical and research programs in multiple disease areas, XBiotech’s True Human ™ antibodies have the ability to take advantage of the body’s natural immunity to fight disease with increased safety, efficacy and tolerance.
XBiotech is a fully integrated global bioscience company dedicated to the discovery, development and commercialization of therapeutic antibodies based on its proprietary True Human ™ technology. XBiotech is currently advancing a strong pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech is also leading the development of innovative biotech manufacturing technologies designed to more quickly, cost effectively and flexibly produce therapies that patients around the world urgently need. For more information, please visit www.xbiotech.com.
Caution regarding forward-looking statements
This press release contains forward-looking statements, including statements regarding the beliefs and expectations of management, which involve significant risks and uncertainties. In some cases, it is possible to identify forward-looking statements by words such as “may”, “will”, “should”, “could”, “expects”, “plans”, “is considering”, “Anticipates”, “believes”, “estimates”, “predicts”, “plans”, “intends” or “continues”, or in the negative form of these terms, or any other comparable terminology, even if not all forward-looking statements contain these identifying terms. Forward-looking statements are subject to risks and uncertainties inherent in forecasting future results and conditions, which could cause such statements to differ materially from the actual results of the company. These risks and uncertainties are subject to the information provided in the “Risk Factors” section of certain of our filings with the SEC. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, as well as the development of the industry in which we operate, may differ materially from the forward-looking statements contained herein. Press release. The forward-looking statements we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.